Psychedelic-assisted mental health treatment has been undergoing a renaissance over the past decade with the emergence of treatments originating from ketamine and psilocybin. And it's not just startups - Big Pharma giants JnJ got their ketamine-derived nasal spray Spravato approved by the FDA back in 2019. This innovation has spread down to patients beyond just novel drugs - leading to treatment combinations and sequences merging traditional therapies with the new. Journey Clinical is part of this rapid growth - creating a platform that allows therapists to incorporate psychedelic-assisted treatments into their practices. Much like GLP-1s in metabolic medicine, an entirely new layer of tools and treatment paradigms are being created in the mental health space - pretty rad when you think about it. (July 2024)